Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has scheduled its Q1 2025 financial results announcement and business update for May 13, 2025, after market close. The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day.
Interested parties can access the listen-only webcast through Allogene's website (www.allogene.com) under the Investors tab. A replay will be available for approximately 30 days. Those wishing to participate in the Q&A session during the conference call must register separately to receive a personal PIN for access.
Allogene Therapeutics (NASDAQ: ALLO), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie CAR T allogeniche (AlloCAR T™) per il cancro e le malattie autoimmuni, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per il 13 maggio 2025, dopo la chiusura dei mercati. La società terrà una conference call e una webcast alle 14:00 PT / 17:00 ET dello stesso giorno.
Gli interessati possono accedere alla webcast in sola ascolto tramite il sito web di Allogene (www.allogene.com) nella sezione Investitori. La registrazione sarà disponibile per circa 30 giorni. Chi desidera partecipare alla sessione di domande e risposte durante la conference call deve registrarsi separatamente per ricevere un PIN personale di accesso.
Allogene Therapeutics (NASDAQ: ALLO), una empresa biotecnológica en etapa clínica enfocada en desarrollar terapias CAR T alogénicas (AlloCAR T™) para el cáncer y enfermedades autoinmunes, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización comercial para el 13 de mayo de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia y una transmisión en vivo a las 2:00 PM PT / 5:00 PM ET del mismo día.
Las partes interesadas pueden acceder a la transmisión solo en modo escucha a través del sitio web de Allogene (www.allogene.com) en la pestaña de Inversores. La repetición estará disponible por aproximadamente 30 días. Quienes deseen participar en la sesión de preguntas y respuestas durante la llamada conferencia deben registrarse por separado para recibir un PIN personal de acceso.
Allogene Therapeutics (NASDAQ: ALLO)는 암 및 자가면역 질환을 위한 동종 CAR T (AlloCAR T™) 치료법 개발에 주력하는 임상 단계 생명공학 회사로, 2025년 1분기 재무 실적 발표 및 사업 업데이트를 2025년 5월 13일 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 2시 PT / 오후 5시 ET에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
관심 있는 분들은 Allogene 웹사이트(www.allogene.com)의 투자자 탭을 통해 청취 전용 웹캐스트에 접속할 수 있습니다. 녹화본은 약 30일간 제공됩니다. 컨퍼런스 콜 중 질의응답 세션에 참여하려면 별도로 등록하여 개인 PIN을 받아야 합니다.
Allogene Therapeutics (NASDAQ : ALLO), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies CAR T allogéniques (AlloCAR T™) pour le cancer et les maladies auto-immunes, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une mise à jour commerciale pour le 13 mai 2025, après la clôture des marchés. La société organisera une conférence téléphonique et une webcast à 14h00 PT / 17h00 ET le même jour.
Les personnes intéressées peuvent accéder à la webcast en mode écoute seule via le site web d'Allogene (www.allogene.com) dans l'onglet Investisseurs. Une rediffusion sera disponible pendant environ 30 jours. Ceux qui souhaitent participer à la session de questions-réponses lors de la conférence téléphonique doivent s'inscrire séparément pour recevoir un code PIN personnel d'accès.
Allogene Therapeutics (NASDAQ: ALLO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung allogener CAR T (AlloCAR T™) Therapien für Krebs und Autoimmunerkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 und ein Geschäftsupdate für den 13. Mai 2025 nach Börsenschluss geplant. Das Unternehmen wird am selben Tag eine Telefonkonferenz und eine Webcast um 14:00 Uhr PT / 17:00 Uhr ET abhalten.
Interessierte können den reinen Hör-Webcast über die Website von Allogene (www.allogene.com) unter dem Bereich Investoren abrufen. Eine Aufzeichnung wird etwa 30 Tage lang verfügbar sein. Wer an der Q&A-Sitzung während der Telefonkonferenz teilnehmen möchte, muss sich separat registrieren, um eine persönliche PIN für den Zugang zu erhalten.
- None.
- None.
- Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-K filed for the year ended December 31, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
When will Allogene Therapeutics (ALLO) report its Q1 2025 earnings?
How can I listen to Allogene Therapeutics' (ALLO) Q1 2025 earnings call?
What time is Allogene Therapeutics' (ALLO) Q1 2025 earnings call?
How long will Allogene Therapeutics' (ALLO) Q1 2025 earnings call replay be available?
